Jim Gallagher

Video

Your First Choice in Complex Biologics Drug Development

The pharmaceutical has made massive investments in complex biologics, a drug class that includes oligonucleotide…

Jim Gallagher2021 年 6 月 1 日

On-Demand Webinar

利用基于证据的次要药效学信息降低项目风险

Safety issues account for about a quarter of the attrition in drug projects and can…

Jim Gallagher2021 年 5 月 28 日

On-Demand Webinar

Stakeholder perspectives: current and potential benefits

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Jim Gallagher2021 年 5 月 26 日

On-Demand Webinar

通过案例研究了解欧洲 HTA 和市场准入的优势和机遇

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Jim Gallagher2021 年 5 月 26 日

On-Demand Webinar

Similarities and differences between SNDS and other claim databases

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Jim Gallagher2021 年 5 月 25 日

On-Demand Webinar

Using Authoring Templates to Write the Right Way

Creating submission-ready regulatory documents that are consistent in presentation, appropriate in content, and formatted to…

Jim Gallagher2021 年 5 月 25 日

On-Demand Webinar

Overview of SNDS and the key working practices to access the database and ongoing SNDS developments

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Jim Gallagher2021 年 5 月 25 日

On-Demand Webinar

PBPK modeling approaches to assess risks associated with bioequivalence in drug development

In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed: Opportunities and challenges in conducting…

Jim Gallagher2021 年 5 月 19 日

Publication

Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate

As model‐informed drug development becomes an integral part of modern approaches to the discovery of…

Jim Gallagher2021 年 5 月 13 日

Publication

Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics

Perhaps the most important lesson learned from the COVID‐19 pandemic is that of preparedness. Enhanced…

Jim Gallagher2021 年 5 月 11 日

Jim Gallagher

Your First Choice in Complex Biologics Drug Development

利用基于证据的次要药效学信息降低项目风险

Stakeholder perspectives: current and potential benefits

通过案例研究了解欧洲 HTA 和市场准入的优势和机遇

Similarities and differences between SNDS and other claim databases

Using Authoring Templates to Write the Right Way

Overview of SNDS and the key working practices to access the database and ongoing SNDS developments

PBPK modeling approaches to assess risks associated with bioequivalence in drug development

Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate

Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics

订阅时事通讯

快捷链接

解决方案

联系我们